Phase
Condition
Muscular Dystrophy
Treatment
Placebo
ATX-01
Clinical Study ID
Ages 18-64 All Genders
Study Summary
Eligibility Criteria
Inclusion
Key Inclusion Criteria:
Participants with a documented clinical diagnosis of DM1 (CTG expansion of >150repeats in DMPK gene measured in peripheral blood mononuclear cells)
Ambulatory, defined as able to complete a 10-meter walk/run test at screeningwithout the use of assistive devices such as canes, walkers, or orthoses, except forankle-foot orthoses
Presence for >3 seconds of grip myotonia as confirmed by a central reader
Exclusion
Key Exclusion Criteria:
Participants with congenital DM1
Medical Research Council Muscle Scale score of less than 4 on ankle dorsiflexion orsignificant tibialis anterior atrophy that prevents a muscle biopsy
Use of mexiletine or other agent for myotonia within 21 days or 5 half-lives,whichever is longer, prior to screening
Study Design
Connect with a study center
Centre Intégré Universitaire de Santé et Services Sociaux du Saguenay-Lac-St-Jean
Chicoutimi, Quebec G7H 5H6
CanadaActive - Recruiting
Institute of Myology
Paris, 75651
FranceActive - Recruiting
The NeMO Clinical Center in Milan, Neurorehabilitation Unit, University of Milan
Milan, 20162
ItalyActive - Recruiting
Fondazione Policlinico A. Gemelli- IRCCS
Rome, 00168
ItalyActive - Recruiting
Hospital Universitario Donostia
Donostia, 20014
SpainActive - Recruiting
St. George's University Hospital
London, SW17 0RE
United KingdomActive - Recruiting
University of Florida
Gainesville, Florida 32610
United StatesActive - Recruiting
University of Kansas Medical Center, Department of Neurology
Fairway, Kansas 66205
United StatesActive - Recruiting
Virginia Commonwealth University
Richmond, Virginia 23298
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.